GenScript Biotech (01548) Report Interpretation

Overview

This event-driven note examines GenScript's collaboration with Lilly TuneLab and argues that it reinforces GenScript's position in the expanding AI-driven drug-discovery ecosystem. JPMorgan retains its Overweight rating and HK$41.00 Dec-2027 target price.

Core views

JPMorgan argues that GenScript's latest agreement with Lilly TuneLab supports its view that GenScript can become a preferred wet-lab partner in AI-driven drug discovery (AIDD). Under the collaboration, GenScript will help TuneLab member companies convert AI-enabled predictions into experimental wet-lab data through standardized, documented protocols. The work includes gene synthesis, protein expression, purification and testing, allowing prioritized sequences generated in dry-lab work to be experimentally assessed more quickly. The institution sees TuneLab's biotech-member base as a potential channel for GenScript to broaden its customer reach. TuneLab had more than 100 biotech members as of June 2026. Those members can use Lilly's AI models for dry-lab discovery and may now gain more direct access to GenScript's wet-lab capabilities. JPMorgan expects this channel could support demand as member companies increase their AIDD activity, while further infrastructure sharing or data integration could eventually improve GenScript's ability to build a closed-loop system linking dry-lab prediction and wet-lab services. TuneLab is described as Lilly's AI/ML platform for providing biotech companies access to proprietary drug-discovery models and underlying data. Lilly stated that the platform's data foundation was supported by more than US$1 billion of investment and spans drug discovery, drug disposition, safety and preclinical research across hundreds of thousands of molecules. Its federated-learning design lets users contribute experimental results without sharing their proprietary underlying data with other parties; as members generate new wet-lab data, the model can improve. JPMorgan believes GenScript's AIDD business can benefit from this feedback process. The note places the collaboration within a broader GenScript growth thesis. GenScript operates in CRO services through LSG, biologics CDMO, enzyme engineering through BestZyme, and a recently deconsolidated cell-therapy segment in which it retains an approximately 45% stake in Legend Biotech. JPMorgan says better-than-expected first-half 2026 results reinforced AIDD as a structural growth driver, with customers moving from proof-of-concept projects toward higher-volume wet-lab validation and model iteration. Automation-driven throughput expansion and a well-funded FY26E capex plan have eased capacity concerns, while stronger-than-expected later-stage business performance provides a second growth engine. Given management's prudent tone, the institution sees scope for further guidance upgrades in 2H26. JPMorgan maintains its Overweight view and identifies customer wins, infrastructure sharing and publications in reputable journals as potential catalysts. GenScript shares were up as much as 15% intraday at the time of writing, compared with a 1.9% rise in the HSHCI. The HK$41.00 Dec-2027 target price is based on a DCF that forecasts free cash flow through 2035, using a 10.8% WACC and 3.0% terminal growth rate.

Analysis framework

JPMorgan links the TuneLab collaboration's specific service scope to GenScript's opportunity to capture AIDD-related wet-lab demand, then assesses the potential customer channel and data-feedback mechanism created by TuneLab's platform. It also relates the event to GenScript's existing operating trends, capacity investments and later-stage business performance, and values the company using a discounted cash flow framework.

Methodology notes

• Valuation methodsDCF (Discounted Cash Flow)

  Discounted cash flow valuation

  JPMorgan estimates GenScript's free cash flow through 2035 and discounts it using a 10.8% WACC, then applies a 3.0% terminal-growth assumption to derive its HK$41 per-share target price.

• Industry AnalysisUpstream-Midstream-Downstream Transmission

  AIDD dry-lab to wet-lab feedback loop

  The report analyzes how Lilly's AI models and member companies' dry-lab predictions can create demand for GenScript's wet-lab validation services, with resulting experimental data feeding back into improved models.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• GenScript Biotech (01548.HK)

  Primary covered company and prospective wet-lab services partner for Lilly TuneLab member companies.

  Strengths

  AIDD-driven wet-lab validation demand, automation-supported throughput expansion, a funded FY26E capex plan and stronger-than-expected later-stage business performance.

  Comparison

  The report notes that Twist Bio will provide antibody-characterization data services and Ginkgo Datapoints will provide discovery-data generation services for TuneLab.

  Risks

  Geopolitical risk, clinical failure of pipeline candidates and regulatory risks.

Key data

• RatingOverweightJPMorgan remains Overweight on GenScript.
• Current priceHK$32.56Price as of 16 Sep 2026.
• Target priceHK$41.00Dec-2027 target price.
• TuneLab member baseMore than 100 biotech companiesReported as of June 2026.
• Lilly investment supporting TuneLab dataMore than US$1 billionSupports data covering drug discovery, disposition, safety and preclinical research.
• DCF WACC10.8%Based on a 3.8% risk-free rate, 6.6% market risk and beta of 1.17.
• DCF terminal growth3.0%Applied after free-cash-flow estimates through 2035.
• Legend Biotech stake~45%GenScript's retained stake is accounted for under the equity method.

Impact & implications

JPMorgan believes the collaboration can position GenScript as an execution partner for biotech companies using AI drug-discovery tools, potentially expanding its client base and supporting a more integrated dry-lab-to-wet-lab data loop. The institution also sees customer wins, infrastructure sharing, journal publications and possible guidance upgrades in 2H26 as relevant developments.

Risks

• Geopolitical risk could affect the rating and price target.
• Clinical failure of pipeline candidates is an explicit downside risk.
• Regulatory risks are an explicit downside risk.

What to watch

• Additional GenScript customer wins through TuneLab.
• Potential infrastructure sharing or data integration between TuneLab and GenScript.
• Research publications in reputable journals.
• Potential management guidance upgrades in 2H26.